Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer and Odyssey Thera Expand Cell-Based Drug-Profiling Collaboration

NEW YORK (GenomeWeb News) – Pfizer will use Odyssey Thera’s cell-based protein-fragment complementation assay (PCA) technology to evaluate the selectivity of Pfizer compounds, Odyssey said today.
Under the terms of the agreement, Odyssey will receive an upfront payment, research and capital expenditure funding, and success-based milestone payments. Further financial details were not disclosed.
The current research collaboration will focus on “large numbers” of Pfizer chemical leads and drug candidates from multiple therapeutic areas, Odyssey said. Odyssey and Pfizer will use the PCA technology and other assays based on automated microscopy to measure changes in cellular signaling networks in response to Pfizer compounds.

The agreement expands upon a May 2005 collaboration between the companies to profile certain Pfizer compounds using the PCA technology.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.